Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

Baron, Frédéric; Suciu, Stefan; Amadori, Sergio; Muus, Petra; Zwierzina, Heinz; Denzlinger, Claudio; Delforge, Michel; Thyss, Antoine; Selleslag, Dominik; Indrak, Karel; Ossenkoppele, Geert; De Witte, Theo

doi:10.3324/haematol.2011.044347

Article (Scientific journals)

Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

Baron, Frédéric; Suciu, Stefan; Amadori, Sergio et al.

2012 • In Haematologica, 97 (4), p. 529–533

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/112511

DOI
10.3324/haematol.2011.044347

PubMed
22102701

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Remicade_EORTC_Haematologica2012.pdf

Publisher postprint (372.12 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

infliximab; tumor necrosis factor alpha; MDS; myelodysplastic syndrome; phase II; randomized

Abstract :

[en] Tumor-necrosis factor alpha activity has been correlated to ineffective erythropoiesis in lower risk myelodysplastic syndromes. Infliximab (Remicade) is an anti-tumor-necrosis factor alpha chimeric antibody that is used in the treatment of patients with heumatoid arthritis or Crohn's disease. Forty-six patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia were included in a randomized phase II study assessing the therapeutic activity of two dosages of infliximab administration (3 mg/kg versus 5 mg/kg). The primary endpoint was the response rate. Responses were observed in 3 of 22 patients (13.1%) randomized to the 3 mg/kg arm, versus 0 of 21 patients randomized in the 5 mg/kg arm. According to the statistical design of the current study, neither of the two infliximab dose schedules tested showed sufficient activity as a single agent in this cohort of unselected patients with early myelodysplastic syndrome.

Disciplines :

Hematology

Author, co-author :

Baron, Frédéric ; Université de Liège - ULiège > GIGA-R : Hématologie

Suciu, Stefan; EORTC Headquarters (Brussels)

Amadori, Sergio; Tor Vergata University Hospital (Rome, Italy)

Muus, Petra; Radboud University Nijmegen Medical Centre (The Netherlands)

Zwierzina, Heinz; Medizinische Universitätsklinik (Innsbruck, Austria)

Denzlinger, Claudio; Medical Clinic III (Stuttgart, Germany)

Delforge, Michel; University Hospital Gasthuisberg (Leuven, Belgium)

Thyss, Antoine; Centre Antoine-Lacassagne (Nice, France)

Selleslag, Dominik; Algemeen Academisch Ziekenhuis St Jan (Bruges-Oostende, Belgium)

Indrak, Karel; University Hospital Olomouc (Czech Republic)

Ossenkoppele, Geert; Vrije Universiteit Medical Centre (Amsterdam, The Netherlands)

De Witte, Theo; Medizinische Universitätsklinik (Innsbruck, Austria)

Language :

English

Title :

Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

Publication date :

2012

Journal title :

Haematologica

ISSN :

0390-6078

eISSN :

1592-8721

Publisher :

Ferrata Storti Foundation, Pavia, Italy

Volume :

Issue :

Pages :

529–533

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 22 February 2012

Statistics

Number of views

147 (3 by ULiège)

Number of downloads

224 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Scott BL, Deeg HJ. Myelodysplastic syndromes. Annu Rev Med. 2010;61:345-358.
de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110(3):620-630.
Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995; 86(1):268-276.
Kerbauy DMB, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-kB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 2005;106(12):3917-3925.
Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995;165(3):538-546.
Musto P, Matera R, Minervini MM, Checchia-de Ambrosio C, Bodenizza C, Falcone A, et al. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. Haematologica. 1994;79(3):265-268.
Verhoef GE, De Schouwer P, Ceuppens JL, van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 1992;6(12):1268-12672.
Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, et al. Serum levels of tumour necrosis factor-alpha predictresponse to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol. 1997;19(3): 197-201.
Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, et al. A role for tumor necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103(1):176-188.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial ATTRACT Study Group. Lancet. 1999;354(9194):1932-1939.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541-1549.
Stasi R, Amadori S. In fliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol. 2002;116(2):334-337.
Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 2004;45(10): 2099-2104.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood. 1998;91(3):1100). Blood. 1997;89(6):2079-2088.
Keane J, Gershon S, Wise RP, Mirabile- Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with in fliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15): 1098-1104.
Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelody splastic syndromes. Blood. 2000; 96:3671-3674.
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. John Wiley, 2002.
Slud EV, Byar DP, Green SB. A comparison of reflected versus test-based confidence intervals for the median survival time, based on censored data. Biometrics. 1984; 40(3):587-600.
Scott BL, Ramakrishnan A, Storer B, Becker PS, Petersdorf S, Estey EH, et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol. 2010;148(6):944-947.
Scott BL, Ramakrishnan A, Fosdal M, Storer B, Becker P, Petersdorf S, et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol. 2010;149(5): 706-710.
Deeg HJ, Gotlib J, Beckham C, Dugan K, Holmberg L, Schubert M, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. Leukemia. 2002;16(2):162-164.
Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, et al. Phase 2 study of lenalidomide in transfusiondependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111(1):86-93.
Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505-2511.